Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	OLIENA Language recovery after stroke App | Video | PDF (278 pp) | Web

Malignant Melanoma

Free Subscription Articles published in Melanoma Res Retrieve available abstracts of 244 articles: HTML format Text format

Single Articles

February 2019
1. DIMITRIOU F, Mangana J, Micaletto S, Braun RP, et al
   Cytokine release syndrome as an important differential diagnosis of severe skin toxicity with organ damage during switch from immunotherapy to targeted therapy in metastatic melanoma.
   Melanoma Res. 2019;29:107-108.
   PubMed     Text format    
   
   
   January 2019
2. PAN B, Lin X, Zhang L, Hong W, et al
   Long noncoding RNA X-inactive specific transcript promotes malignant melanoma progression and oxaliplatin resistance.
   Melanoma Res. 2019 Jan 11. doi: 10.1097/CMR.0000000000000560.
   PubMed     Text format     Abstract available
   
   
   
3. KHURANA S, Baldeo C, Joseph RW
   Inositol hexaphosphate plus inositol induced complete remission in stage IV melanoma: a case report.
   Melanoma Res. 2019 Jan 5. doi: 10.1097/CMR.0000000000000577.
   PubMed     Text format     Abstract available
   
   
   
4. MOTOFEI IG
   Melanoma and autoimmunity: spontaneous regressions as a possible model for new therapeutic approaches.
   Melanoma Res. 2019 Jan 4. doi: 10.1097/CMR.0000000000000573.
   PubMed     Text format     Abstract available
   
   
   
5. TIO D, Kasiem FR, Willemsen M, van Doorn R, et al
   Expression of cancer/testis antigens in cutaneous melanoma: a systematic review.
   Melanoma Res. 2019 Jan 4. doi: 10.1097/CMR.0000000000000569.
   PubMed     Text format     Abstract available
   
   
   
6. MANCINI S, Crocetti E, Bucchi L, Pimpinelli N, et al
   Time trends and age-period-cohort analysis of cutaneous malignant melanoma incidence rates in the Romagna Region (northern Italy), 1986-2014.
   Melanoma Res. 2019 Jan 4. doi: 10.1097/CMR.0000000000000570.
   PubMed     Text format     Abstract available
   
   
   December 2018
7. BAFALOUKOS D, Papaxoinis G, Linardou H, Diamantopoulos P, et al
   Prognostic significance of distant metastasis-free interval in patients with relapsed melanoma treated with BRAF with or without MEK inhibitors.
   Melanoma Res. 2018 Dec 28. doi: 10.1097/CMR.0000000000000562.
   PubMed     Text format     Abstract available
   
   
   
8. LEE WJ, Lee MH, Kim HT, Won CH, et al
   Prognostic significance of CD163 expression and its correlation with cyclooxygenase-2 and vascular endothelial growth factor expression in cutaneous melanoma.
   Melanoma Res. 2018 Dec 19. doi: 10.1097/CMR.0000000000000549.
   PubMed     Text format     Abstract available
   
   
   
9. CRINCOLI E, Moliterni E, Catania F, Didona D, et al
   Correlation of serum tryptase levels with total number of nevi, Breslow thickness, ulceration, and mitotic index in melanoma patients: evaluation of a promising prognostic marker.
   Melanoma Res. 2018 Dec 15. doi: 10.1097/CMR.0000000000000561.
   PubMed     Text format     Abstract available
   
   
   
10. BOURSI B, Werner TJ, Gholami S, Margalit O, et al
    Physiologic colonic fluorine-18-fluorodeoxyglucose uptake may predict response to immunotherapy in patients with metastatic melanoma.
    Melanoma Res. 2018 Dec 14. doi: 10.1097/CMR.0000000000000566.
    PubMed     Text format     Abstract available
    
    
    
11. OTTES VASCONCELOS R, Serini S, de Souza Votto AP, Santos Trindade G, et al
    Combination of omega-3 fatty acids and cisplatin as a potential alternative strategy for personalized therapy of metastatic melanoma: an in-vitro study.
    Melanoma Res. 2018 Dec 13. doi: 10.1097/CMR.0000000000000564.
    PubMed     Text format     Abstract available
    
    
    
12. MAHAPATRA L, Andruska N, Mao C, Gruber SB, et al
    Protein kinase C-alpha is upregulated by IMP1 in melanoma and is linked to poor survival.
    Melanoma Res. 2018 Dec 12. doi: 10.1097/CMR.0000000000000558.
    PubMed     Text format     Abstract available
    
    
    
13. CORAZZA M, Dika E, Maietti E, Musmeci D, et al
    Eruptive cherry angiomas and skin melanoma: a fortuitous association?
    Melanoma Res. 2018 Dec 12. doi: 10.1097/CMR.0000000000000563.
    PubMed     Text format     Abstract available
    
    
    
14. BLOCK MS, Nevala WK, Pang YP, Allred JB, et al
    A pilot clinical trial testing topical resiquimod and a xenopeptide as immune adjuvants for a melanoma vaccine targeting MART-1.
    Melanoma Res. 2018 Dec 4. doi: 10.1097/CMR.0000000000000556.
    PubMed     Text format     Abstract available
    
    
    
15. CIMMINIELLO C, Indini A, Di Guardo L, Prisciandaro M, et al
    Pembrolizumab in the treatment of advanced/metastatic melanoma: a single-center institution experience.
    Melanoma Res. 2018 Dec 4. doi: 10.1097/CMR.0000000000000539.
    PubMed     Text format     Abstract available
    
    
    
16. 
    A unique gene expression signature is significantly differentially expressed in tumor-positive or tumor-negative sentinel lymph nodes in patients with melanoma: Erratum.
    Melanoma Res. 2018;28:655.
    PubMed     Text format    
    
    
    November 2018
17. DISANO JA, Huffnagle I, Gowda R, Spiegelman VS, et al
    Loss of miR-155 upregulates WEE1 in metastatic melanoma.
    Melanoma Res. 2018 Nov 29. doi: 10.1097/CMR.0000000000000545.
    PubMed     Text format     Abstract available
    
    
    
18. YANG J, Chen S, Li Y, Wang B, et al
    Incidence rate and risk factors for suicide death in patients with skin malignant melanoma: a Surveillance, Epidemiology, and End Results analysis.
    Melanoma Res. 2018 Nov 26. doi: 10.1097/CMR.0000000000000559.
    PubMed     Text format     Abstract available
    
    
    
19. YAN J, Xu L, Yu J, Wu X, et al
    Prognostic role of NRAS isoforms in Chinese melanoma patients.
    Melanoma Res. 2018 Nov 26. doi: 10.1097/CMR.0000000000000557.
    PubMed     Text format     Abstract available
    
    
    
20. BIANCONI F, Crocetti E, Grisci C, Primieri C, et al
    What has changed in the epidemiology of skin melanoma in central Italy during the past 20 years?
    Melanoma Res. 2018 Nov 26. doi: 10.1097/CMR.0000000000000551.
    PubMed     Text format     Abstract available
    
    
    
21. HU Y, Wang Q, Zhu XH
    MiR-135b is a novel oncogenic factor in cutaneous melanoma by targeting LATS2.
    Melanoma Res. 2018 Nov 21. doi: 10.1097/CMR.0000000000000524.
    PubMed     Text format     Abstract available
    
    
    
22. SARUBI HC, Pereira NB, Gomes CC, Gomez RS, et al
    Molecular and immunohistochemical analyses of uveal melanoma patient cohort.
    Melanoma Res. 2018 Nov 21. doi: 10.1097/CMR.0000000000000523.
    PubMed     Text format     Abstract available
    
    
    
23. WU K, Wang W, Ye Y, Huang J, et al
    Integration of protein interaction and gene co-expression information for identification of melanoma candidate genes.
    Melanoma Res. 2018 Nov 19. doi: 10.1097/CMR.0000000000000525.
    PubMed     Text format     Abstract available
    
    
    
24. ROMANO S, D'Arrigo P, Tufano M, Staibano S, et al
    TRAF2 and FKBP51 as possible markers for identification of suitable melanoma tumors for tumor necrosis factor-alpha inhibition.
    Melanoma Res. 2018 Nov 19. doi: 10.1097/CMR.0000000000000553.
    PubMed     Text format     Abstract available
    
    
    
25. URBONAS V, Smailyte G, Urbonaite GV, Dulskas A, et al
    Natural killer cell-based immunotherapy: a new fighter against melanoma?
    Melanoma Res. 2018 Nov 19. doi: 10.1097/CMR.0000000000000552.
    PubMed     Text format     Abstract available
    
    
    
26. MASCITTI M, Santarelli A, Sartini D, Rubini C, et al
    Analysis of nicotinamide N-methyltransferase in oral malignant melanoma and potential prognostic significance.
    Melanoma Res. 2018 Nov 13. doi: 10.1097/CMR.0000000000000548.
    PubMed     Text format     Abstract available
    
    
    
27. DUNDR P, Simon K, Nemejcova K, Bartu M, et al
    Stathmin is a potential therapeutic target but not a prognostic marker in melanoma: an immunohistochemical study of 323 melanocytic lesions.
    Melanoma Res. 2018 Nov 12. doi: 10.1097/CMR.0000000000000550.
    PubMed     Text format     Abstract available
    
    
    
28. SALMI S, Siiskonen H, Sironen R, Tyynela-Korhonen K, et al
    The number and localization of CD68+ and CD163+ macrophages in different stages of cutaneous melanoma.
    Melanoma Res. 2018 Nov 5. doi: 10.1097/CMR.0000000000000522.
    PubMed     Text format     Abstract available
    
    
    
29. YANG N, Lu J, Lu Y, Guo J, et al
    Primary malignant melanotic melanoma and hypomelanotic melanoma of the female urethra: case series and a review of the literature in China.
    Melanoma Res. 2018 Nov 2. doi: 10.1097/CMR.0000000000000521.
    PubMed     Text format     Abstract available
    
    
    October 2018
30. PEPIN F, Julien AS, Fugaru I, Lihimdi N, et al
    Regression rate of choroidal melanoma following iodine-125 brachytherapy is not associated with metastatic spread.
    Melanoma Res. 2018 Oct 31. doi: 10.1097/CMR.0000000000000540.
    PubMed     Text format     Abstract available
    
    
    
31. ABBOTT JL, Qureshi MM, Truong MT, Sahni D, et al
    Comparing survival outcomes in early stage desmoplastic melanoma with or without adjuvant radiation.
    Melanoma Res. 2018 Oct 31. doi: 10.1097/CMR.0000000000000532.
    PubMed     Text format     Abstract available
    
    
    
32. ZHANG D, Wang Z, Shang D, Yu J, et al
    Incidence and prognosis of brain metastases in cutaneous melanoma patients: a population-based study.
    Melanoma Res. 2018 Oct 30. doi: 10.1097/CMR.0000000000000538.
    PubMed     Text format     Abstract available
    
    
    
33. DRAGO JZ, Lawrence D, Livingstone E, Zimmer L, et al
    Clinical experience with combination BRAF/MEK inhibitors for melanoma with brain metastases: a real-life multicenter study.
    Melanoma Res. 2018 Oct 29. doi: 10.1097/CMR.0000000000000527.
    PubMed     Text format     Abstract available
    
    
    
34. BUYUKKAPU BAY S, Kebudi R, Zulfikar B
    Cutaneous adverse event associated with vemurafenib in a 3-year-old pediatric patient with BRAF mutation-positive metastatic melanoma and factor X deficiency.
    Melanoma Res. 2018 Oct 29. doi: 10.1097/CMR.0000000000000537.
    PubMed     Text format     Abstract available
    
    
    
35. VUJIC I, Gandini S, Stanganelli I, Fierro MT, et al
    A meta-analysis of melanoma risk in industrial workers.
    Melanoma Res. 2018 Oct 26. doi: 10.1097/CMR.0000000000000531.
    PubMed     Text format     Abstract available
    
    
    
36. MARCOVAL J, Sabate-Llobera A, Bermejo J, Fornons-Servent R, et al
    Hibernoma as an incidental finding in the 18F-FDG PET/CT of a patient with melanoma.
    Melanoma Res. 2018 Oct 24. doi: 10.1097/CMR.0000000000000530.
    PubMed     Text format     Abstract available
    
    
    
37. ABDEL-RAHMAN O
    Population-based validation of the National Cancer Comprehensive Network recommendations for baseline imaging workup of cutaneous melanoma.
    Melanoma Res. 2018 Oct 22. doi: 10.1097/CMR.0000000000000528.
    PubMed     Text format     Abstract available
    
    
    
38. BELLOCQ D, Roy P, Kodjikian L, Mathis T, et al
    20-year assessment of metastatic latency and subsequent time to death after proton therapy for uveal melanomas.
    Melanoma Res. 2018 Oct 12. doi: 10.1097/CMR.0000000000000519.
    PubMed     Text format     Abstract available
    
    
    
39. VAN LAAR RK, Lincoln MT, van Laar BJ
    A plasma microRNA biomarker of melanoma as a personalised assessment of treatment response.
    Melanoma Res. 2018 Oct 12. doi: 10.1097/CMR.0000000000000492.
    PubMed     Text format     Abstract available
    
    
    
40. PETRELLI F, Ardito R, Merelli B, Lonati V, et al
    Prognostic and predictive role of elevated lactate dehydrogenase in patients with melanoma treated with immunotherapy and BRAF inhibitors: a systematic review and meta-analysis.
    Melanoma Res. 2018 Oct 10. doi: 10.1097/CMR.0000000000000520.
    PubMed     Text format     Abstract available
    
    
    
41. DABROSIN N, Sloth Juul K, Baehr Georgsen J, Andrup S, et al
    Innate immune cell infiltration in melanoma metastases affects survival and is associated with BRAFV600E mutation status.
    Melanoma Res. 2018 Oct 5. doi: 10.1097/CMR.0000000000000515.
    PubMed     Text format     Abstract available
    
    
    
42. LASKE J, Meier F, Bauer A, Beissert S, et al
    Tattoo-associated complications of metastatic melanoma treated with dabrafenib and trametinib.
    Melanoma Res. 2018;28:485-487.
    PubMed     Text format    
    
    
    September 2018
43. HALFPENNY NJA, Scott DA, Thompson JC, Gurung B, et al
    A practical approach to predict expansion of evidence networks: a case study in treatment-naive advanced melanoma.
    Melanoma Res. 2018 Sep 29. doi: 10.1097/CMR.0000000000000513.
    PubMed     Text format     Abstract available
    
    
    
44. HWANG SJE, Park JJW, Wakade D, Chou S, et al
    Cutaneous adverse events of anti-programmed death 1 antibodies combined with anti-cytotoxic T-lymphocyte-associated protein 4 therapy use in patients with metastatic melanoma.
    Melanoma Res. 2018 Sep 29. doi: 10.1097/CMR.0000000000000518.
    PubMed     Text format     Abstract available
    
    
    
45. YIP RHL, Lee LH, Schaeffer DF, Horst BA, et al
    Lymphocytic gastritis induced by pembrolizumab in a patient with metastatic melanoma.
    Melanoma Res. 2018 Sep 25. doi: 10.1097/CMR.0000000000000502.
    PubMed     Text format     Abstract available
    
    
    
46. YIN G, Guo W, Chen X, Huang Z, et al
    Prognosis of endoscopic surgery and traditional open resection in mucosal melanoma of the nasal cavity and paranasal sinus.
    Melanoma Res. 2018 Sep 25. doi: 10.1097/CMR.0000000000000516.
    PubMed     Text format     Abstract available
    
    
    
47. GHATE S, Ionescu-Ittu R, Burne R, Ndife B, et al
    Patterns of treatment and BRAF testing with immune checkpoint inhibitors and targeted therapy in patients with metastatic melanoma presumed to be BRAF positive.
    Melanoma Res. 2018 Sep 21. doi: 10.1097/CMR.0000000000000504.
    PubMed     Text format     Abstract available
    
    
    
48. SCAINI MC, Pigozzo J, Pizzi M, Manicone M, et al
    Clonal heterogeneity of melanoma in a paradigmatic case study: future prospects for circulating melanoma cells.
    Melanoma Res. 2018 Sep 14. doi: 10.1097/CMR.0000000000000510.
    PubMed     Text format     Abstract available
    
    
    
49. TINGFENG X, Fuqiang P, Dong L
    Expression and clinical significance of S100 family genes in patients with melanoma.
    Melanoma Res. 2018 Sep 13. doi: 10.1097/CMR.0000000000000512.
    PubMed     Text format     Abstract available
    
    
    
50. TARHINI A, Ghate SR, Ionescu-Ittu R, Manceur AM, et al
    Postsurgical treatment landscape and economic burden of locoregional and distant recurrence in patients with operable nonmetastatic melanoma.
    Melanoma Res. 2018 Sep 13. doi: 10.1097/CMR.0000000000000507.
    PubMed     Text format     Abstract available
    
    
    
51. SHAH S, Luke JJ, Jacene HA, Chen T, et al
    Results from phase II trial of HSP90 inhibitor, STA-9090 (ganetespib), in metastatic uveal melanoma.
    Melanoma Res. 2018 Sep 11. doi: 10.1097/CMR.0000000000000509.
    PubMed     Text format     Abstract available
    
    
    
52. SEREMET T, Planken S, Schwarze JK, Jansen Y, et al
    Successful treatment with intralesional talimogene laherparepvec in two patients with immune checkpoint inhibitors refractory advanced melanoma.
    Melanoma Res. 2018 Sep 11. doi: 10.1097/CMR.0000000000000501.
    PubMed     Text format     Abstract available
    
    
    
53. CHRISTENSEN L, Scott J, Bordeaux J
    Use of gene expression profile testing as a prognostic tool in early-stage cutaneous melanoma - compelling but not ready for primetime.
    Melanoma Res. 2018 Sep 11. doi: 10.1097/CMR.0000000000000506.
    PubMed     Text format     Abstract available
    
    
    
54. DE MELO AC, Wainstein AJA, Buzaid AC, Thuler LCS, et al
    Melanoma signature in Brazil: epidemiology, incidence, mortality, and trend lessons from a continental mixed population country in the past 15 years.
    Melanoma Res. 2018 Sep 10. doi: 10.1097/CMR.0000000000000511.
    PubMed     Text format     Abstract available
    
    
    
55. ZHAO B, Cheng X, Zhou X
    The BET-bromodomain inhibitor JQ1 mitigates vemurafenib drug resistance in melanoma.
    Melanoma Res. 2018 Sep 5. doi: 10.1097/CMR.0000000000000497.
    PubMed     Text format     Abstract available
    
    
    
56. TROMME I, Sacre L, Hammouch F, Richez P, et al
    Melanoma diagnosis: predictive value of macroscopic changes observed by the patient.
    Melanoma Res. 2018 Sep 5. doi: 10.1097/CMR.0000000000000496.
    PubMed     Text format     Abstract available
    
    
    
57. NYE A, Collins JD, Porter CL, Montes de Oca M, et al
    Predictive genetic profiles for regional lymph node metastasis in primary cutaneous melanoma: a case-matched pilot study.
    Melanoma Res. 2018 Sep 1. doi: 10.1097/CMR.0000000000000499.
    PubMed     Text format     Abstract available
    
    
    August 2018
58. KANG R, Lipner S
    Assessment of internet sources on subungual melanoma.
    Melanoma Res. 2018 Aug 30. doi: 10.1097/CMR.0000000000000508.
    PubMed     Text format     Abstract available
    
    
    
59. TAN SY, Najita J, Li X, Strazzulla LC, et al
    Clinicopathologic features correlated with paradoxical outcomes in stage IIC versus IIIA melanoma patients.
    Melanoma Res. 2018 Aug 30. doi: 10.1097/CMR.0000000000000483.
    PubMed     Text format     Abstract available
    
    
    
60. DIAMANTOPOULOS PT, Stoungioti S, Anastasopoulou A, Papaxoinis G, et al
    Incomplete Vogt-Koyanagi-Harada disease following treatment with encorafenib and binimetinib for metastatic melanoma.
    Melanoma Res. 2018 Aug 30. doi: 10.1097/CMR.0000000000000505.
    PubMed     Text format     Abstract available
    
    
    
61. SWORDS DS, Andtbacka RHI, Bowles TL, Hyngstrom JR, et al
    Routine retrieval of pelvic sentinel lymph nodes for melanoma rarely adds prognostic information or alters management.
    Melanoma Res. 2018 Aug 29. doi: 10.1097/CMR.0000000000000498.
    PubMed     Text format     Abstract available
    
    
    
62. KENESSEY I, Kramer Z, Istvan L, Cserepes MT, et al
    Inhibition of epidermal growth factor receptor improves antitumor efficacy of vemurafenib in BRAF-mutant human melanoma in preclinical model.
    Melanoma Res. 2018 Aug 17. doi: 10.1097/CMR.0000000000000488.
    PubMed     Text format     Abstract available
    
    
    
63. HERBERT A, Koo MM, Barclay ME, Greenberg DC, et al
    Stage-specific incidence trends of melanoma in an English region, 1996-2015: longitudinal analyses of population-based data.
    Melanoma Res. 2018 Aug 13. doi: 10.1097/CMR.0000000000000489.
    PubMed     Text format     Abstract available
    
    
    
64. YAN J, Wu X, Yu J, Ma M, et al
    Establishment and characterization of melanoma patient-derived xenograft models for preclinical evaluation of novel therapeutics.
    Melanoma Res. 2018 Aug 6. doi: 10.1097/CMR.0000000000000494.
    PubMed     Text format     Abstract available
    
    
    
65. GROGAN N, Swami U, Bossler AD, Zakharia Y, et al
    Toxicities with targeted therapies after immunotherapy in metastatic melanoma.
    Melanoma Res. 2018 Aug 6. doi: 10.1097/CMR.0000000000000493.
    PubMed     Text format     Abstract available
    
    
    
66. LIU G, Wang Y, Fei F, Wang X, et al
    Clinical characteristics and preliminary morphological observation of 47 cases of primary anorectal malignant melanomas.
    Melanoma Res. 2018 Aug 3. doi: 10.1097/CMR.0000000000000491.
    PubMed     Text format     Abstract available
    
    
    
67. MONTAUDIE H, Picard A, Panaia-Ferrari P, Boukari F, et al
    Painful acute thyroiditis following a first cure of Ipilimumab plus Nivolumab for metastatic melanoma.
    Melanoma Res. 2018;28:368-369.
    PubMed     Text format    
    
    
    July 2018
68. NICHOLAS MN, Khoja L, Atenafu EG, Hogg D, et al
    Prognostic factors for first-line therapy and overall survival of metastatic uveal melanoma: The Princess Margaret Cancer Centre experience.
    Melanoma Res. 2018 Jul 31. doi: 10.1097/CMR.0000000000000468.
    PubMed     Text format     Abstract available
    
    
    
69. SUN H, Chen Y, Chen Y, Liu D, et al
    Primary malignant melanoma of the cervix: 14 cases and literature overview.
    Melanoma Res. 2018 Jul 23. doi: 10.1097/CMR.0000000000000469.
    PubMed     Text format     Abstract available
    
    
    
70. AYDOGMUS-OZTURK F, Gunaydin K, Ozturk M, Jahan H, et al
    Effect of Sideritis leptoclada against HT-144 human malignant melanoma.
    Melanoma Res. 2018 Jul 19. doi: 10.1097/CMR.0000000000000487.
    PubMed     Text format     Abstract available
    
    
    
71. SAGLAM O, Naqvi SMH, Zhang Y, Mesa T, et al
    Female genitourinary tract melanoma: mutation analysis with clinicopathologic correlation: a single-institution experience.
    Melanoma Res. 2018 Jul 19. doi: 10.1097/CMR.0000000000000480.
    PubMed     Text format     Abstract available
    
    
    
72. NUNES LF, Quintella Mendes GL, Koifman RJ
    Acral melanoma: a retrospective cohort from the Brazilian National Cancer Institute (INCA).
    Melanoma Res. 2018 Jul 16. doi: 10.1097/CMR.0000000000000476.
    PubMed     Text format     Abstract available
    
    
    
73. OLAVERRIA SALAVAGGIONE GN, Duggan MC, Carson WE
    Analysis of MLN4924 (pevonedistat) as a potential therapeutic agent in malignant melanoma.
    Melanoma Res. 2018 Jul 16. doi: 10.1097/CMR.0000000000000474.
    PubMed     Text format     Abstract available
    
    
    
74. BRUNSSEN A, Jansen L, Eisemann N, Waldmann A, et al
    Long-term relative survival from melanoma in Germany 1997-2013.
    Melanoma Res. 2018 Jul 16. doi: 10.1097/CMR.0000000000000482.
    PubMed     Text format     Abstract available
    
    
    
75. HUTCHINSON PE, Halsall JA, Popovici S, Papadogeorgakis E, et al
    Compromised vitamin D receptor signalling in malignant melanoma is associated with tumour progression and mitogen-activated protein kinase activity.
    Melanoma Res. 2018 Jul 12. doi: 10.1097/CMR.0000000000000475.
    PubMed     Text format     Abstract available
    
    
    
76. FERRIS LK, Gerami P, Skelsey MK, Peck G, et al
    Real-world performance and utility of a noninvasive gene expression assay to evaluate melanoma risk in pigmented lesions.
    Melanoma Res. 2018 Jul 12. doi: 10.1097/CMR.0000000000000478.
    PubMed     Text format     Abstract available
    
    
    
77. LYTH J
    Conditional recurrence-free survival in patients with primary stage I-II cutaneous malignant melanoma - a population-based study.
    Melanoma Res. 2018 Jul 9. doi: 10.1097/CMR.0000000000000479.
    PubMed     Text format     Abstract available
    
    
    
78. LAMIAUX M, Scalbert C, Lepesant P, Desmedt E, et al
    Severe skin toxicity with organ damage under the combination of targeted therapy following immunotherapy in metastatic melanoma.
    Melanoma Res. 2018 Jul 6. doi: 10.1097/CMR.0000000000000472.
    PubMed     Text format     Abstract available
    
    
    
79. GORLOV I, Orlow I, Ringelberg C, Hernando E, et al
    Identification of gene expression levels in primary melanoma associated with clinically meaningful characteristics.
    Melanoma Res. 2018 Jul 2. doi: 10.1097/CMR.0000000000000473.
    PubMed     Text format     Abstract available
    
    
    
80. GOMEZ-LEON N, Pacheco-Barcia V, Ballesteros AI, Fraga J, et al
    Skeletal muscle and solitary bone metastases from malignant melanoma: multimodality imaging and oncological outcome.
    Melanoma Res. 2018 Jul 2. doi: 10.1097/CMR.0000000000000466.
    PubMed     Text format     Abstract available
    
    
    June 2018
81. URBONAS V, Smailyte G
    Combination of cytokine-directed and anti-programmed cell death protein 1 therapy - a new attractive option in melanoma treatment?
    Melanoma Res. 2018 Jun 29. doi: 10.1097/CMR.0000000000000470.
    PubMed     Text format     Abstract available
    
    
    
82. RAMBHIA PH, Honda K, Arbesman J
    Nivolumab induced inflammation of seborrheic keratoses: a novel cutaneous manifestation in a metastatic melanoma patient.
    Melanoma Res. 2018 Jun 29. doi: 10.1097/CMR.0000000000000477.
    PubMed     Text format     Abstract available
    
    
    
83. MENSHAWY A, Eltonob AA, Barkat SA, Ghanem A, et al
    Nivolumab monotherapy or in combination with ipilimumab for metastatic melanoma: systematic review and meta-analysis of randomized-controlled trials.
    Melanoma Res. 2018 Jun 27. doi: 10.1097/CMR.0000000000000467.
    PubMed     Text format     Abstract available
    
    
    
84. PUZA CJ, Barbas AS, Mosca PJ
    Outcomes of patients with a pretransplant history of early-stage melanoma.
    Melanoma Res. 2018 Jun 25. doi: 10.1097/CMR.0000000000000471.
    PubMed     Text format     Abstract available
    
    
    
85. MORGADO-CARRASCO D, Moreno-Rivera N, Fusta-Novell X, Garcia-Herrera A, et al
    Histiocytoid Sweet's syndrome during combined therapy with BRAF and MEK inhibitors for metastatic melanoma.
    Melanoma Res. 2018;28:256-257.
    PubMed     Text format    
    
    
    May 2018
86. HAFLIGER EM, Ramelyte E, Mangana J, Kunz M, et al
    Metastatic acral lentiginous melanoma in a tertiary referral center in Switzerland: a systematic analysis.
    Melanoma Res. 2018 May 29. doi: 10.1097/CMR.0000000000000465.
    PubMed     Text format     Abstract available
    
    
    
87. IACONO D, Cinausero M, Gerratana L, Angione V, et al
    Tumour-infiltrating lymphocytes, programmed death ligand 1 and cyclooxygenase-2 expression in skin melanoma of elderly patients: clinicopathological correlations.
    Melanoma Res. 2018 May 22. doi: 10.1097/CMR.0000000000000462.
    PubMed     Text format     Abstract available
    
    
    
88. BRUTTING J, Bergmann M, Garzarolli M, Rauschenberg R, et al
    Unmet information needs of patients with melanoma in Germany.
    Melanoma Res. 2018 May 21. doi: 10.1097/CMR.0000000000000464.
    PubMed     Text format     Abstract available
    
    
    
89. TETERYCZ P, Jagodzinska-Mucha P, Cybulska-Stopa B, Mariuk-Jarema A, et al
    High baseline neutrophil-to-lymphocyte ratio predicts worse outcome in patients with metastatic BRAF-positive melanoma treated with BRAF and MEK inhibitors.
    Melanoma Res. 2018 May 18. doi: 10.1097/CMR.0000000000000461.
    PubMed     Text format     Abstract available
    
    
    
90. FACINA AS, Facina G, Guerreiro da Silva IDC, Correa SAA, et al
    Pregnancy and the apoptotic pathway in experimental melanoma.
    Melanoma Res. 2018 May 17. doi: 10.1097/CMR.0000000000000452.
    PubMed     Text format     Abstract available
    
    
    
91. ZHOU X, Zeng Y, Jiang H, Xia L, et al
    Predictive value of excision repair cross-complementing group 2 gene Lys751Gln and Asp312Asn polymorphisms in melanoma risk.
    Melanoma Res. 2018 May 15. doi: 10.1097/CMR.0000000000000463.
    PubMed     Text format     Abstract available
    
    
    
92. TSOUTSOS D, Papadopoulos S, Kehagias G, Mara A, et al
    Epidemiological trends in the diagnosis of melanoma in a Southern European population: analysis of a large database from a tertiary referral center.
    Melanoma Res. 2018 May 14. doi: 10.1097/CMR.0000000000000456.
    PubMed     Text format     Abstract available
    
    
    
93. AFZAL MZ, Shirai K
    Immune checkpoint inhibitor (anti-CTLA-4, anti-PD-1) therapy alone versus immune checkpoint inhibitor (anti-CTLA-4, anti-PD-1) therapy in combination with anti-RANKL denosumuab in malignant melanoma: a retrospective analysis at a tertiary care center.
    Melanoma Res. 2018 May 10. doi: 10.1097/CMR.0000000000000459.
    PubMed     Text format     Abstract available
    
    
    
94. TENGDA L, Shuping L, Mingli G, Jie G, et al
    Serum exosomal microRNAs as potent circulating biomarkers for melanoma.
    Melanoma Res. 2018 May 10. doi: 10.1097/CMR.0000000000000450.
    PubMed     Text format     Abstract available
    
    
    
95. ASCIERTO PA, Bastholt L, Ferrucci PF, Hansson J, et al
    The impact of patient characteristics and disease-specific factors on first-line treatment decisions for BRAF-mutated melanoma: results from a European expert panel study.
    Melanoma Res. 2018 May 10. doi: 10.1097/CMR.0000000000000455.
    PubMed     Text format     Abstract available
    
    
    
96. MOSHE M, Levi A, Ad-El D, Ben-Amitai D, et al
    Malignant melanoma clinically mimicking pyogenic granuloma: comparison of clinical evaluation and histopathology.
    Melanoma Res. 2018 May 10. doi: 10.1097/CMR.0000000000000451.
    PubMed     Text format     Abstract available
    
    
    
97. SCHOUWENBURG MG, Jochems A, Leeneman B, Franken MG, et al
    Vemurafenib in BRAF-mutant metastatic melanoma patients in real-world clinical practice: prognostic factors associated with clinical outcomes.
    Melanoma Res. 2018 May 10. doi: 10.1097/CMR.0000000000000453.
    PubMed     Text format     Abstract available
    
    
    
98. GONG HZ, Zheng HY, Li J
    The clinical significance of KIT mutations in melanoma: a meta-analysis.
    Melanoma Res. 2018 May 9. doi: 10.1097/CMR.0000000000000454.
    PubMed     Text format     Abstract available
    
    
    April 2018
99. SEBESTYEN T, Mohos A, Liszkay G, Somlai B, et al
    Correlation with lymphocyte infiltration, but lack of prognostic significance of MECA-79-positive high endothelial venules in primary malignant melanoma.
    Melanoma Res. 2018 Apr 20. doi: 10.1097/CMR.0000000000000457.
    PubMed     Text format     Abstract available
    
    
    
100. LEE WJ, Lee YJ, Shin HJ, Won CH, et al
     Clinicopathological significance of tumor-infiltrating lymphocytes and programmed death-1 expression in cutaneous melanoma: a comparative study on clinical subtypes.
     Melanoma Res. 2018 Apr 9. doi: 10.1097/CMR.0000000000000449.
     PubMed     Text format     Abstract available
     
     
     
101. SIA DIT, Thaung C, O'Hanlon-Brown C, Cohen VML, et al
     Immune privilege: failure of immunotherapy in controlling metastatic cutaneous melanoma to the eye.
     Melanoma Res. 2018 Apr 9. doi: 10.1097/CMR.0000000000000443.
     PubMed     Text format     Abstract available
     
     
     
102. BASSOLI S, Pellegrini C, Longo C, Di Nardo L, et al
     Clinical, dermoscopic, and confocal features of nevi and melanomas in a multiple primary melanoma patient with the MITF p.E318K homozygous mutation.
     Melanoma Res. 2018;28:166-169.
     PubMed     Text format    
     
     
     
103. TAKAHASHI A, Tsutsumida A, Namikawa K, Yamazaki N, et al
     Fulminant type 1 diabetes associated with nivolumab in a patient with metastatic melanoma.
     Melanoma Res. 2018;28:159-160.
     PubMed     Text format    
     
     
     March 2018
104. TURNER KA, Manouchehri JM, Kalafatis M
     Sensitization of recombinant human tumor necrosis factor-related apoptosis-inducing ligand-resistant malignant melanomas by quercetin.
     Melanoma Res. 2018 Mar 28. doi: 10.1097/CMR.0000000000000447.
     PubMed     Text format     Abstract available
     
     
     
105. TERNOV NK, Lambine TL, Wagenblast ALH, Clasen-Linde E, et al
     Targeted ultrasound and fine-needle aspiration cytology for sentinel node diagnostics in early-stage melanoma: a validation study.
     Melanoma Res. 2018 Mar 27. doi: 10.1097/CMR.0000000000000448.
     PubMed     Text format     Abstract available
     
     
     
106. CHESNEY J, Imbert-Fernandez Y, Telang S, Baum M, et al
     Potential clinical and immunotherapeutic utility of talimogene laherparepvec for patients with melanoma after disease progression on immune checkpoint inhibitors and BRAF inhibitors.
     Melanoma Res. 2018 Mar 21. doi: 10.1097/CMR.0000000000000444.
     PubMed     Text format     Abstract available
     
     
     
107. KLEEMANN J, Hrgovic I, Ter-Nedden J, Kleimann P, et al
     Fatty acid receptor GPR120: a novel marker for human melanoma.
     Melanoma Res. 2018 Mar 21. doi: 10.1097/CMR.0000000000000445.
     PubMed     Text format     Abstract available
     
     
     
108. LADE-KELLER J, Yuusufi S, Riber-Hansen R, Steiniche T, et al
     Telomerase reverse transcriptase promoter mutations and solar elastosis in cutaneous melanoma.
     Melanoma Res. 2018 Mar 21. doi: 10.1097/CMR.0000000000000446.
     PubMed     Text format     Abstract available
     
     
     
109. NASARRE P, Bonilla IV, Metcalf JS, Hilliard EG, et al
     TRAF3-interacting protein 3, a new oncotarget, promotes tumor growth in melanoma.
     Melanoma Res. 2018 Mar 16. doi: 10.1097/CMR.0000000000000440.
     PubMed     Text format     Abstract available
     
     
     
110. GESKIN LJ, Damiano JJ, Patrone CC, Butterfield LH, et al
     Three antigen-loading methods in dendritic cell vaccines for metastatic melanoma.
     Melanoma Res. 2018 Mar 14. doi: 10.1097/CMR.0000000000000441.
     PubMed     Text format     Abstract available
     
     
     
111. DE UNAMUNO B, Garcia-Casado Z, Banuls J, Requena C, et al
     CDKN2A germline alterations in melanoma patients with personal or familial history of pancreatic cancer.
     Melanoma Res. 2018 Mar 14. doi: 10.1097/CMR.0000000000000442.
     PubMed     Text format     Abstract available
     
     
     
112. STOWMAN AM, Hickman AW, Mauldin IS, Mahmutovic A, et al
     Lymphoid aggregates in desmoplastic melanoma have features of tertiary lymphoid structures.
     Melanoma Res. 2018 Mar 13. doi: 10.1097/CMR.0000000000000439.
     PubMed     Text format     Abstract available
     
     
     
113. FOLEY KC, Nishimura MI, Moore TV
     Combination immunotherapies implementing adoptive T-cell transfer for advanced-stage melanoma.
     Melanoma Res. 2018 Mar 8. doi: 10.1097/CMR.0000000000000436.
     PubMed     Text format     Abstract available
     
     
     February 2018
114. MACHIRAJU D, Moll I, Gebhardt C, Sucker A, et al
     STAT5 expression correlates with recurrence and survival in melanoma patients treated with interferon-alpha.
     Melanoma Res. 2018 Feb 26. doi: 10.1097/CMR.0000000000000435.
     PubMed     Text format     Abstract available
     
     
     
115. DIMITRIOU F, Frauchiger AL, Urosevic-Maiwald M, Naegeli MC, et al
     Sarcoid-like reactions in patients receiving modern melanoma treatment.
     Melanoma Res. 2018 Feb 26. doi: 10.1097/CMR.0000000000000437.
     PubMed     Text format     Abstract available
     
     
     
116. GONZALEZ-CAO M, Mayo de Las Casas C, Jordana Ariza N, Manzano JL, et al
     Early evolution of BRAFV600 status in the blood of melanoma patients correlates with clinical outcome and identifies patients refractory to therapy.
     Melanoma Res. 2018 Feb 23. doi: 10.1097/CMR.0000000000000432.
     PubMed     Text format     Abstract available
     
     
     
117. TESTORI AA, Suciu S, van Akkooi ACJ, Suppa M, et al
     Lymph node ratio as a prognostic factor in melanoma: results from European Organization for Research and Treatment of Cancer 18871, 18952, and 18991 studies.
     Melanoma Res. 2018 Feb 9. doi: 10.1097/CMR.0000000000000433.
     PubMed     Text format     Abstract available
     
     
     
118. GANZETTI G, Sartini D, Campanati A, Rubini C, et al
     Nicotinamide N-methyltransferase: potential involvement in cutaneous malignant melanoma.
     Melanoma Res. 2018 Feb 7. doi: 10.1097/CMR.0000000000000430.
     PubMed     Text format     Abstract available
     
     
     
119. YANAGITA M, Luke JJ, Hodi FS, Janne PA, et al
     Isolation and characterization of circulating melanoma cells by size filtration and fluorescent in-situ hybridization.
     Melanoma Res. 2018 Feb 5. doi: 10.1097/CMR.0000000000000431.
     PubMed     Text format     Abstract available
     
     
     
120. KOTHAPALLI A, Khattak MA
     Safety and efficacy of anti-PD-1 therapy for metastatic melanoma and non-small-cell lung cancer in patients with viral hepatitis: a case series.
     Melanoma Res. 2018 Feb 5. doi: 10.1097/CMR.0000000000000434.
     PubMed     Text format     Abstract available
     
     
     
121. EISENSTEIN A, Panova IP, Chung HJ, Goldberg LJ, et al
     Quantitative assessment of neuropilin-2 as a simple and sensitive diagnostic assay for spitzoid melanocytic lesions.
     Melanoma Res. 2018;28:71-75.
     PubMed     Text format     Abstract available
     
     
     
122. ISAKOVIC AM, Petricevic SM, Ristic SM, Popadic DM, et al
     In vitro and in vivo antimelanoma effect of ethyl ester cyclohexyl analog of ethylenediamine dipropanoic acid.
     Melanoma Res. 2018;28:8-20.
     PubMed     Text format     Abstract available
     
     
     January 2018
123. GEUKES FOPPEN MH, Boogerd W, Blank CU, van Thienen JV, et al
     Clinical and radiological response of BRAF inhibition and MEK inhibition in patients with brain metastases from BRAF-mutated melanoma.
     Melanoma Res. 2018 Jan 19. doi: 10.1097/CMR.0000000000000429.
     PubMed     Text format     Abstract available
     
     
     
124. NARDIN C, Mateus C, Texier M, Lanoy E, et al
     Tolerance and outcomes of stereotactic radiosurgery combined with anti-programmed cell death-1 (pembrolizumab) for melanoma brain metastases.
     Melanoma Res. 2018 Jan 19. doi: 10.1097/CMR.0000000000000413.
     PubMed     Text format     Abstract available
     
     
     
125. ROSE AM, Radia UK, Luo R, Kalirai H, et al
     Multiple primary malignancies and prolonged survival in a patient with widespread metastatic cutaneous melanoma.
     Melanoma Res. 2018 Jan 17. doi: 10.1097/CMR.0000000000000426.
     PubMed     Text format    
     
     
     
126. ZHU W, Li S, Zou B, Liu H, et al
     Expressions and clinical significance of HER4 and CD44 in sinonasal mucosal malignant melanoma.
     Melanoma Res. 2018 Jan 5. doi: 10.1097/CMR.0000000000000428.
     PubMed     Text format     Abstract available
     
     
     
127. DANISH H, Ferris MJ, Balagamwala E, Switchenko JM, et al
     Comparative outcomes and toxicities for ruthenium-106 versus palladium-103 in the treatment of choroidal melanoma.
     Melanoma Res. 2018 Jan 3. doi: 10.1097/CMR.0000000000000420.
     PubMed     Text format     Abstract available
     
     
     December 2017
128. DEL CARPIO HUERTA LP, Mas Castells M, Anguera Palacios G, Sullivan I, et al
     A novel KRAS mutation in metastasic conjunctival melanoma: a case report and literature review.
     Melanoma Res. 2017 Dec 20. doi: 10.1097/CMR.0000000000000423.
     PubMed     Text format     Abstract available
     
     
     
129. WEITMAN ES, Perez M, Thompson JF, Andtbacka RHI, et al
     Quality of life patient-reported outcomes for locally advanced cutaneous melanoma.
     Melanoma Res. 2017 Dec 19. doi: 10.1097/CMR.0000000000000425.
     PubMed     Text format     Abstract available
     
     
     
130. GALLO S, Coha V, Caravelli D, Becco P, et al
     BRAF-inhibitors can exert control of disease in BRAF T599I mutated melanoma: a case report.
     Melanoma Res. 2017 Dec 11. doi: 10.1097/CMR.0000000000000417.
     PubMed     Text format     Abstract available
     
     
     
131. BISSCHOP C, Ter Elst A, Bosman LJ, Platteel I, et al
     Rapid BRAF mutation tests in patients with advanced melanoma: comparison of immunohistochemistry, Droplet Digital PCR, and the Idylla Mutation Platform.
     Melanoma Res. 2017 Dec 11. doi: 10.1097/CMR.0000000000000421.
     PubMed     Text format     Abstract available
     
     
     
132. SEREMET T, Planken S, Schreuer M, Jansen Y, et al
     Illustrative cases for monitoring by quantitative analysis of BRAF/NRAS ctDNA mutations in liquid biopsies of metastatic melanoma patients who gained clinical benefits from anti-PD1 antibody therapy.
     Melanoma Res. 2017 Dec 8. doi: 10.1097/CMR.0000000000000415.
     PubMed     Text format     Abstract available
     
     
     
133. LOYSON T, Werbrouck E, Punie K, Bonne L, et al
     Hemorrhage of liver and bone metastases as a result of rapid response to dual BRAF/MEK inhibition in metastatic melanoma: a case report.
     Melanoma Res. 2017 Dec 5. doi: 10.1097/CMR.0000000000000419.
     PubMed     Text format     Abstract available
     
     
     
134. MENZIES S, Barry R, Ormond P
     Multiple primary melanoma: a single centre retrospective review.
     Melanoma Res. 2017;27:638-640.
     PubMed     Text format     Abstract available
     
     
     
135. SCHINZARI G, Rossi E, Cassano A, Dadduzio V, et al
     Cisplatin, dacarbazine and vinblastine as first line chemotherapy for liver metastatic uveal melanoma in the era of immunotherapy: a single institution phase II study.
     Melanoma Res. 2017;27:591-595.
     PubMed     Text format     Abstract available
     
     
     
136. HALLMEYER S, Gonzalez R, Lawson DH, Cranmer LD, et al
     Vemurafenib treatment for patients with locally advanced, unresectable stage IIIC or metastatic melanoma and activating exon 15 BRAF mutations other than V600E.
     Melanoma Res. 2017;27:585-590.
     PubMed     Text format     Abstract available
     
     
     
137. ROBINSON JP, Rebecca VW, Kircher DA, Silvis MR, et al
     Resistance mechanisms to genetic suppression of mutant NRAS in melanoma.
     Melanoma Res. 2017;27:545-557.
     PubMed     Text format     Abstract available
     
     
     
138. VAN DER WEYDEN L, Arends MJ, Brenn T, Tuting T, et al
     Widespread spontaneous hyperproliferation, melanosis and melanoma in Hgf-Cdk4R24C mice.
     Melanoma Res. 2017 Dec 1. doi: 10.1097/CMR.0000000000000414.
     PubMed     Text format    
     
     
     November 2017
139. BRANCA M, Orso S, Molinari RC, Xu H, et al
     Is nonmetastatic cutaneous melanoma predictable through genomic biomarkers?
     Melanoma Res. 2017 Nov 29. doi: 10.1097/CMR.0000000000000412.
     PubMed     Text format     Abstract available
     
     
     
140. CHESNEY J, Awasthi S, Curti B, Hutchins L, et al
     Phase IIIb safety results from an expanded-access protocol of talimogene laherparepvec for patients with unresected, stage IIIB-IVM1c melanoma.
     Melanoma Res. 2017 Nov 22. doi: 10.1097/CMR.0000000000000399.
     PubMed     Text format     Abstract available
     
     
     
141. HADDEN NJ, McIntosh JRD, Jay S, Whittaker PJ, et al
     Prognostic factors in patients with metastatic spinal cord compression secondary to melanoma: a systematic review.
     Melanoma Res. 2017 Nov 14. doi: 10.1097/CMR.0000000000000411.
     PubMed     Text format     Abstract available
     
     
     
142. KUO JC, Lilly LB, Hogg D
     Immune checkpoint inhibitor therapy in a liver transplant recipient with a rare subtype of melanoma: a case report and literature review.
     Melanoma Res. 2017 Nov 14. doi: 10.1097/CMR.0000000000000410.
     PubMed     Text format     Abstract available
     
     
     
143. BRZOZOWSKA M, Wierzba W, Sliwczynski A, Swierkowski M, et al
     Analysis of survival of patients treated with vemurafenib, ipilimumab and dabrafenib for advanced skin melanoma in daily clinical practice (Real-World Data): retrospective analysis of patients treated under drug/reimbursement programmes in Poland in 2
     Melanoma Res. 2017 Nov 8. doi: 10.1097/CMR.0000000000000408.
     PubMed     Text format     Abstract available
     
     
     October 2017
144. PACHMANN K, Willecke-Hochmuth R, Schneider K, Kaatz M, et al
     Circulating epithelial tumor cells as a prognostic tool for malignant melanoma.
     Melanoma Res. 2017 Oct 25. doi: 10.1097/CMR.0000000000000407.
     PubMed     Text format     Abstract available
     
     
     
145. TANG Y, Xie C, Zhang Y, Qin Y, et al
     Overexpression of mRNA-decapping enzyme 1a predicts disease-specific survival in malignant melanoma.
     Melanoma Res. 2017 Oct 25. doi: 10.1097/CMR.0000000000000406.
     PubMed     Text format     Abstract available
     
     
     
146. UPRETY D, Bista A, Chennamadhavuni A, Niroula A, et al
     Survival trends among patients with metastatic melanoma in the pretargeted and the post-targeted era: a US population-based study.
     Melanoma Res. 2017 Oct 11. doi: 10.1097/CMR.0000000000000394.
     PubMed     Text format     Abstract available
     
     
     
147. FAILING JJ, Yan Y, Porrata LF, Markovic SN, et al
     Lymphocyte-to-monocyte ratio is associated with survival in pembrolizumab-treated metastatic melanoma patients.
     Melanoma Res. 2017 Oct 9. doi: 10.1097/CMR.0000000000000404.
     PubMed     Text format     Abstract available
     
     
     
148. SHEN X, Fan Y, Cao S
     A review of primary malignant melanoma arising in an ovarian cystic teratoma.
     Melanoma Res. 2017 Oct 9. doi: 10.1097/CMR.0000000000000402.
     PubMed     Text format     Abstract available
     
     
     
149. ALESSI C, Scapulatempo Neto C, Viana CR, Vazquez VL, et al
     PD-1/PD-L1 and VEGF-A/VEGF-C expression in lymph node microenvironment and association with melanoma metastasis and survival.
     Melanoma Res. 2017 Oct 3. doi: 10.1097/CMR.0000000000000396.
     PubMed     Text format     Abstract available
     
     
     
150. TSIOGKA A, Jansky GL, Bauer JW, Koelblinger P, et al
     Fulminant type 1 diabetes after adjuvant ipilimumab therapy in cutaneous melanoma.
     Melanoma Res. 2017;27:524-525.
     PubMed     Text format    
     
     
     
151. ABOUDARAM A, Modesto A, Chaltiel L, Gomez-Roca C, et al
     Concurrent radiotherapy for patients with metastatic melanoma and receiving anti-programmed-death 1 therapy: a safe and effective combination.
     Melanoma Res. 2017;27:485-491.
     PubMed     Text format     Abstract available
     
     
     September 2017
152. MARTINEZ-GARCIA MA, Riveiro-Falkenbach E, Rodriguez-Peralto JL, Nagore E, et al
     A prospective multicenter cohort study of cutaneous melanoma: clinical staging and potential associations with HIF-1alpha and VEGF expressions.
     Melanoma Res. 2017 Sep 6. doi: 10.1097/CMR.0000000000000393.
     PubMed     Text format     Abstract available
     
     
     
153. DE SOUZA NETO FP, Bernardes SS, Marinello PC, Melo GP, et al
     Metformin: oxidative and proliferative parameters in-vitro and in-vivo models of murine melanoma.
     Melanoma Res. 2017 Sep 4. doi: 10.1097/CMR.0000000000000391.
     PubMed     Text format     Abstract available
     
     
     
154. YUKI A, Takenouchi T, Takatsuka S, Ishiguro T, et al
     A case of pure red cell aplasia during nivolumab therapy for cardiac metastatic melanoma.
     Melanoma Res. 2017 Sep 1. doi: 10.1097/CMR.0000000000000392.
     PubMed     Text format     Abstract available
     
     
     
155. TAHA T, Tzuk-Shina T, Forschner I, Bar-Sela G, et al
     Acute motor and sensory axonal neuropathy related to treatment with MEK inhibitors in a patient with advanced melanoma.
     Melanoma Res. 2017 Sep 1. doi: 10.1097/CMR.0000000000000390.
     PubMed     Text format     Abstract available
     
     
     August 2017
156. LI Y, Umbach DM, Li L
     Putative genomic characteristics of BRAF V600K versus V600E cutaneous melanoma.
     Melanoma Res. 2017 Aug 28. doi: 10.1097/CMR.0000000000000388.
     PubMed     Text format     Abstract available
     
     
     
157. TARHINI AA, Floros T, Lin HM, Lin Y, et al
     A unique gene expression signature is significantly differentially expressed in tumor-positive or tumor-negative sentinel lymph nodes in patients with melanoma.
     Melanoma Res. 2017 Aug 18. doi: 10.1097/CMR.0000000000000383.
     PubMed     Text format     Abstract available
     
     
     
158. GLITZA IC, Guha-Thakurta N, D'Souza NM, Amaria RN, et al
     Bevacizumab as an effective treatment for radiation necrosis after radiotherapy for melanoma brain metastases.
     Melanoma Res. 2017 Aug 16. doi: 10.1097/CMR.0000000000000389.
     PubMed     Text format     Abstract available
     
     
     
159. PURI A, Homsi J
     The safety of pembrolizumab in metastatic melanoma and rheumatoid arthritis.
     Melanoma Res. 2017 Aug 16. doi: 10.1097/CMR.0000000000000387.
     PubMed     Text format     Abstract available
     
     
     
160. BARBARIC J, Laversanne M, Znaor A
     Malignant melanoma incidence trends in a Mediterranean population following socioeconomic transition and war: results of age-period-cohort analysis in Croatia, 1989-2013.
     Melanoma Res. 2017 Aug 10. doi: 10.1097/CMR.0000000000000385.
     PubMed     Text format     Abstract available
     
     
     
161. GARDNER LJ, Ward M, Andtbacka RHI, Boucher KM, et al
     Risk factors for development of melanoma brain metastasis and disease progression: a single-center retrospective analysis.
     Melanoma Res. 2017 Aug 10. doi: 10.1097/CMR.0000000000000382.
     PubMed     Text format     Abstract available
     
     
     
162. ROGIERS A, Borght SV, Tuand K, Wolter P, et al
     Response to targeted therapy in two patients with metastatic melanoma carrying rare BRAF exon 15 mutations: A598_T599insV and V600_K601delinsE.
     Melanoma Res. 2017 Aug 10. doi: 10.1097/CMR.0000000000000376.
     PubMed     Text format     Abstract available
     
     
     
163. GOGAS HJ, Karalexi MA, Dessypris N, Antoniadis AG, et al
     The role of depression and personality traits in patients with melanoma: a South-European study.
     Melanoma Res. 2017 Aug 10. doi: 10.1097/CMR.0000000000000380.
     PubMed     Text format     Abstract available
     
     
     
164. GLADFELTER P, Darwish NHE, Mousa SA
     Current status and future direction in the management of malignant melanoma.
     Melanoma Res. 2017 Aug 10. doi: 10.1097/CMR.0000000000000379.
     PubMed     Text format     Abstract available
     
     
     
165. GRANGE F, Mohr P, Harries M, Ehness R, et al
     Economic burden of advanced melanoma in France, Germany and the UK: a retrospective observational study (Melanoma Burden-of-Illness Study).
     Melanoma Res. 2017 Aug 10. doi: 10.1097/CMR.0000000000000372.
     PubMed     Text format     Abstract available
     
     
     
166. STOWMAN AM, Hickman AW, Gru AA, Slingluff CL Jr, et al
     Histopathologic review of negative sentinel lymph node biopsies in thin melanomas: an argument for the routine use of immunohistochemistry.
     Melanoma Res. 2017;27:369-376.
     PubMed     Text format     Abstract available
     
     
     
167. DE ROSA F, Ridolfi L, Fiammenghi L, Petrini M, et al
     Dendritic cell vaccination for metastatic melanoma: a 14-year monoinstitutional experience.
     Melanoma Res. 2017;27:351-357.
     PubMed     Text format     Abstract available
     
     
     
168. SANGALLI A, Orlandi E, Poli A, Maurichi A, et al
     Sex-specific effect of RNASEL rs486907 and miR-146a rs2910164 polymorphisms' interaction as a susceptibility factor for melanoma skin cancer.
     Melanoma Res. 2017;27:309-314.
     PubMed     Text format     Abstract available
     
     
     July 2017
169. SOSSAU D, Kofler L, Eigentler T
     Type 1 diabetes mellitus caused by treatment with low-dose interferon-alpha in a melanoma patient.
     Melanoma Res. 2017 Jul 19. doi: 10.1097/CMR.0000000000000381.
     PubMed     Text format     Abstract available
     
     
     
170. BORGHI A, Corazza M, Virgili A, Lambertini AG, et al
     Impact of socioeconomic status and district of residence on cutaneous malignant melanoma prognosis: a survival study on incident cases between 1991 and 2011 in the province of Ferrara, northern Italy.
     Melanoma Res. 2017 Jul 18. doi: 10.1097/CMR.0000000000000378.
     PubMed     Text format     Abstract available
     
     
     
171. GRATZ V, Luttmann N, Haase O, Langan EA, et al
     Meningeal melanomatosis following discontinuation of dabrafenib: implications for the maintenance of long-term complete remission.
     Melanoma Res. 2017 Jul 18. doi: 10.1097/CMR.0000000000000373.
     PubMed     Text format     Abstract available
     
     
     
172. GAUCI ML, Laly P, Sarah LL, Behin A, et al
     Focal necrotizing myopathy with 'dropped-head syndrome' induced by cobimetinib in metastatic melanoma.
     Melanoma Res. 2017 Jul 7. doi: 10.1097/CMR.0000000000000377.
     PubMed     Text format     Abstract available
     
     
     June 2017
173. WANDLER A, Riber-Hansen R, Hager H, Hamilton-Dutoit SJ, et al
     Quantification of microRNA-21 and microRNA-125b in melanoma tissue.
     Melanoma Res. 2017 Jun 13. doi: 10.1097/CMR.0000000000000374.
     PubMed     Text format     Abstract available
     
     
     
174. TOMIZUKA T, Namikawa K, Higashi T
     Characteristics of melanoma in Japan: a nationwide registry analysis 2011-2013.
     Melanoma Res. 2017 Jun 12. doi: 10.1097/CMR.0000000000000375.
     PubMed     Text format     Abstract available
     
     
     
175. SOARES CD, Borges CF, Sena-Filho M, Almeida OP, et al
     Prognostic significance of cyclooxygenase 2 and phosphorylated Akt1 overexpression in primary nonmetastatic and metastatic cutaneous melanomas.
     Melanoma Res. 2017 Jun 9. doi: 10.1097/CMR.0000000000000368.
     PubMed     Text format     Abstract available
     
     
     
176. DAVICK JJ, Wick MR, Gru AA
     Development of a biclonal cutaneous T-cell lymphoproliferative process during treatment with immune checkpoint inhibitors for metastatic melanoma.
     Melanoma Res. 2017 Jun 1. doi: 10.1097/CMR.0000000000000371.
     PubMed     Text format     Abstract available
     
     
     
177. GIUDICE G, Robusto F, Vestita M, Annoscia P, et al
     Single-stage excision and sentinel lymph node biopsy in cutaneous melanoma in selected patients: a retrospective case-control study.
     Melanoma Res. 2017 Jun 1. doi: 10.1097/CMR.0000000000000370.
     PubMed     Text format     Abstract available
     
     
     
178. WANG Y, Wen XZ, Ba HJ, Li DD, et al
     A prognostic model for resectable acral melanoma patients on the basis of preoperative inflammatory markers.
     Melanoma Res. 2017 Jun 1. doi: 10.1097/CMR.0000000000000365.
     PubMed     Text format     Abstract available
     
     
     
179. MIRZA S, Hill E, Ludlow SP, Nanjappa S, et al
     Checkpoint inhibitor-associated drug reaction with eosinophilia and systemic symptom syndrome.
     Melanoma Res. 2017;27:271-273.
     PubMed     Text format     Abstract available
     
     
     
180. HAUEIS SA, Kranzlin P, Mangana J, Cheng PF, et al
     Does the distribution pattern of brain metastases during BRAF inhibitor therapy reflect phenotype switching?
     Melanoma Res. 2017;27:231-237.
     PubMed     Text format     Abstract available
     
     
     May 2017
181. FURDOVA A, Sramka M, Chorvath M, Kralik G, et al
     Clinical experience of stereotactic radiosurgery at a linear accelerator for intraocular melanoma.
     Melanoma Res. 2017 May 17. doi: 10.1097/CMR.0000000000000364.
     PubMed     Text format     Abstract available
     
     
     
182. MANGANA J, Cheng PF, Kaufmann C, Amann VC, et al
     Multicenter, real-life experience with checkpoint inhibitors and targeted therapy agents in advanced melanoma patients in Switzerland.
     Melanoma Res. 2017 May 15. doi: 10.1097/CMR.0000000000000359.
     PubMed     Text format     Abstract available
     
     
     
183. GUADAGNI S, Fiorentini G, Clementi M, Palumbo G, et al
     MGMT methylation correlates with melphalan pelvic perfusion survival in stage III melanoma patients: a pilot study.
     Melanoma Res. 2017 May 10. doi: 10.1097/CMR.0000000000000367.
     PubMed     Text format     Abstract available
     
     
     
184. LAKHTER AJ, Naidu SR
     Cyclic AMP-Epac signaling pathway contributes to repression of PUMA transcription in melanoma cells.
     Melanoma Res. 2017 May 4. doi: 10.1097/CMR.0000000000000363.
     PubMed     Text format     Abstract available
     
     
     
185. HOLTKAMP LHJ, Read RL, Emmett L, Thompson JF, et al
     Futility of imaging to stage melanoma patients with a positive sentinel lymph node.
     Melanoma Res. 2017 May 4. doi: 10.1097/CMR.0000000000000362.
     PubMed     Text format     Abstract available
     
     
     
186. STABLER S, Becquart C, Dumezy F, Terriou L, et al
     Hemophagocytic lymphohistiocytosis in patients with metastatic malignant melanoma.
     Melanoma Res. 2017 May 3. doi: 10.1097/CMR.0000000000000354.
     PubMed     Text format     Abstract available
     
     
     April 2017
187. MENDT M, Cardier JE
     Activation of the CXCR4 chemokine receptor enhances biological functions associated with B16 melanoma liver metastasis.
     Melanoma Res. 2017 Apr 25. doi: 10.1097/CMR.0000000000000346.
     PubMed     Text format     Abstract available
     
     
     
188. KYRGIDIS A, Lallas A, Moscarella E, Longo C, et al
     Does pregnancy influence melanoma prognosis? A meta-analysis.
     Melanoma Res. 2017 Apr 20. doi: 10.1097/CMR.0000000000000334.
     PubMed     Text format     Abstract available
     
     
     
189. DIAMANTOPOULOS PT, Gaggadi M, Kassi E, Benopoulou O, et al
     Late-onset nivolumab-mediated pneumonitis in a patient with melanoma and multiple immune-related adverse events.
     Melanoma Res. 2017 Apr 17. doi: 10.1097/CMR.0000000000000355.
     PubMed     Text format     Abstract available
     
     
     
190. PISCIOLI F, Pusiol T, Roncati L
     Critical points of T1 stage in primary melanoma.
     Melanoma Res. 2017 Apr 13. doi: 10.1097/CMR.0000000000000357.
     PubMed     Text format    
     
     
     
191. MURER C, Kranzlin-Stieger P, French LE, Dummer R, et al
     Successful treatment with imatinib after nilotinib and ipilimumab in a c-kit-mutated advanced melanoma patient: a case report.
     Melanoma Res. 2017 Apr 13. doi: 10.1097/CMR.0000000000000358.
     PubMed     Text format     Abstract available
     
     
     
192. TARHINI AA, Moschos SJ, Lin Y, Lin HM, et al
     Safety and efficacy of the antiganglioside GD3 antibody ecromeximab (KW2871) combined with high-dose interferon-alpha2b in patients with metastatic melanoma.
     Melanoma Res. 2017 Apr 7. doi: 10.1097/CMR.0000000000000353.
     PubMed     Text format     Abstract available
     
     
     
193. THOMSON CH, Cassell O, Peach H, Holloway S, et al
     Neuropathic pain and quality of life after wide local excision and sentinel lymph node biopsy for melanoma: a multicentre study.
     Melanoma Res. 2017;27:121-125.
     PubMed     Text format     Abstract available
     
     
     
194. ROGIERS A, Wolter P, Bechter O
     Dabrafenib plus trametinib rechallenge in four melanoma patients who previously progressed on this combination.
     Melanoma Res. 2017;27:164-167.
     PubMed     Text format     Abstract available
     
     
     
195. BLACKMON JT, Dhawan R, Terry NL, Conry RM, et al
     Response of BRAF inhibitor-associated squamous cell lung carcinoma to drug withdrawal.
     Melanoma Res. 2017;27:159-163.
     PubMed     Text format     Abstract available
     
     
     
196. AMODE R, Baroudjian B, Kowal A, Jebali M, et al
     Anti-programmed cell death protein 1 tolerance and efficacy after ipilimumab immunotherapy: observational study of 39 patients.
     Melanoma Res. 2017;27:110-115.
     PubMed     Text format     Abstract available
     
     
     March 2017
197. DE GIORGI V, Grazzini M, Benemei S, Marchionni N, et al
     beta-Blocker use and reduced disease progression in patients with thick melanoma: 8 years of follow-up.
     Melanoma Res. 2017 Mar 24. doi: 10.1097/CMR.0000000000000317.
     PubMed     Text format     Abstract available
     
     
     
198. HINTZSCHE JD, Gorden NT, Amato CM, Kim J, et al
     Whole-exome sequencing identifies recurrent SF3B1 R625 mutation and comutation of NF1 and KIT in mucosal melanoma.
     Melanoma Res. 2017 Mar 14. doi: 10.1097/CMR.0000000000000345.
     PubMed     Text format     Abstract available
     
     
     
199. LEON-FERRE RA, Kottschade LA, Block MS, McWilliams RR, et al
     Association between the use of surveillance PET/CT and the detection of potentially salvageable occult recurrences among patients with resected high-risk melanoma.
     Melanoma Res. 2017 Mar 14. doi: 10.1097/CMR.0000000000000344.
     PubMed     Text format     Abstract available
     
     
     
200. CARRERA C, Gual A, Diaz A, Puig-Butille JA, et al
     Prognostic role of the histological subtype of melanoma on the hands and feet in Caucasians.
     Melanoma Res. 2017 Mar 14. doi: 10.1097/CMR.0000000000000340.
     PubMed     Text format     Abstract available
     
     
     
201. FALLENI M, Savi F, Tosi D, Agape E, et al
     M1 and M2 macrophages' clinicopathological significance in cutaneous melanoma.
     Melanoma Res. 2017 Mar 7. doi: 10.1097/CMR.0000000000000352.
     PubMed     Text format     Abstract available
     
     
     
202. FUKUDA K, Funakoshi T, Sakurai T, Nakamura Y, et al
     Peptide-pulsed dendritic cell vaccine in combination with carboplatin and paclitaxel chemotherapy for stage IV melanoma.
     Melanoma Res. 2017 Mar 3. doi: 10.1097/CMR.0000000000000342.
     PubMed     Text format     Abstract available
     
     
     
203. BLASIG H, Bender C, Hassel JC, Eigentler TK, et al
     Reinduction of PD1-inhibitor therapy: first experience in eight patients with metastatic melanoma.
     Melanoma Res. 2017 Mar 2. doi: 10.1097/CMR.0000000000000341.
     PubMed     Text format     Abstract available
     
     
     
204. DE GIORGI V, Gori A, Savarese I, D'Errico A, et al
     Clinical and dermoscopic features of truly amelanotic plantar melanoma.
     Melanoma Res. 2017 Mar 1. doi: 10.1097/CMR.0000000000000337.
     PubMed     Text format     Abstract available
     
     
     
205. LOQUAI C, Schmidtmann I, Garzarolli M, Kaatz M, et al
     Interactions from complementary and alternative medicine in patients with melanoma.
     Melanoma Res. 2017 Mar 1. doi: 10.1097/CMR.0000000000000339.
     PubMed     Text format     Abstract available
     
     
     February 2017
206. DESVIGNES C, Abirached H, Templier C, Drumez E, et al
     BRAF inhibitor discontinuation and rechallenge in advanced melanoma patients with a complete initial treatment response.
     Melanoma Res. 2017 Feb 24. doi: 10.1097/CMR.0000000000000350.
     PubMed     Text format     Abstract available
     
     
     
207. TAS F, Erturk K
     Scalp melanoma is associated with high mitotic rate and is a poor prognostic factor for recurrence and outcome.
     Melanoma Res. 2017 Feb 23. doi: 10.1097/CMR.0000000000000351.
     PubMed     Text format     Abstract available
     
     
     
208. VIZKELETI L, Kiss T, Koroknai V, Ecsedi S, et al
     Altered integrin expression patterns shown by microarray in human cutaneous melanoma.
     Melanoma Res. 2017 Feb 23. doi: 10.1097/CMR.0000000000000322.
     PubMed     Text format     Abstract available
     
     
     
209. ITCHINS M, Ascierto PA, Menzies AM, Oatley M, et al
     A multireferral centre retrospective cohort analysis on the experience in treatment of metastatic uveal melanoma and utilization of sequential liver-directed treatment and immunotherapy.
     Melanoma Res. 2017 Feb 22. doi: 10.1097/CMR.0000000000000343.
     PubMed     Text format     Abstract available
     
     
     
210. MADU MF, Timmerman P, Wouters MW, van der Hiel B, et al
     PET/CT surveillance detects asymptomatic recurrences in stage IIIB and IIIC melanoma patients: a prospective cohort study.
     Melanoma Res. 2017 Feb 20. doi: 10.1097/CMR.0000000000000347.
     PubMed     Text format     Abstract available
     
     
     
211. LI FJ, Li LM, Zhang RH, Xu C, et al
     The role of 5-hydroxymethylcytosine in melanoma.
     Melanoma Res. 2017 Feb 20. doi: 10.1097/CMR.0000000000000349.
     PubMed     Text format     Abstract available
     
     
     
212. TESIO V, Ribero S, Castelli L, Bassino S, et al
     Psychological characteristics of early-stage melanoma patients: a cross-sectional study on 204 patients.
     Melanoma Res. 2017 Feb 15. doi: 10.1097/CMR.0000000000000348.
     PubMed     Text format     Abstract available
     
     
     
213. RIBERO S, Longo C, Specchio F, Piana S, et al
     Lymph nodes' capsular naevi are associated with high naevus count in melanoma patients: a case-control study.
     Melanoma Res. 2017 Feb 1. doi: 10.1097/CMR.0000000000000328.
     PubMed     Text format     Abstract available
     
     
     January 2017
214. PELLEGRINI C, Maturo MG, Martorelli C, Suppa M, et al
     Characterization of melanoma susceptibility genes in high-risk patients from Central Italy.
     Melanoma Res. 2017 Jan 31. doi: 10.1097/CMR.0000000000000323.
     PubMed     Text format     Abstract available
     
     
     
215. LINO-SILVA LS, Salcedo-Hernandez RA, Garcia-Perez L, Meneses-Garcia A, et al
     Basal neutrophil-to-lymphocyte ratio is associated with overall survival in melanoma.
     Melanoma Res. 2017 Jan 25. doi: 10.1097/CMR.0000000000000333.
     PubMed     Text format     Abstract available
     
     
     
216. GRAY A, Grushchak S, Mudaliar K, Kliethermes S, et al
     The microenvironment in primary cutaneous melanoma with associated spontaneous tumor regression: evaluation for T-regulatory cells and the presence of an immunosuppressive microenvironment.
     Melanoma Res. 2017 Jan 25. doi: 10.1097/CMR.0000000000000331.
     PubMed     Text format     Abstract available
     
     
     
217. OBEID JM, Hu Y, Erdag G, Leick KM, et al
     The heterogeneity of tumor-infiltrating CD8+ T cells in metastatic melanoma distorts their quantification: how to manage heterogeneity?
     Melanoma Res. 2017 Jan 21. doi: 10.1097/CMR.0000000000000330.
     PubMed     Text format     Abstract available
     
     
     
218. OBA J, Esmaeli B, Ellerhorst JA, Lyons GR, et al
     Trends in hepatocyte growth factor, insulin-like growth factor 1, thyroid-stimulating hormone, and leptin expression levels in uveal melanoma patient serum and tumor tissues: correlation to disease progression.
     Melanoma Res. 2017 Jan 21. doi: 10.1097/CMR.0000000000000329.
     PubMed     Text format     Abstract available
     
     
     
219. LADWA R, Atkinson V
     The cessation of anti-PD-1 antibodies of complete responders in metastatic melanoma.
     Melanoma Res. 2017 Jan 17. doi: 10.1097/CMR.0000000000000336.
     PubMed     Text format     Abstract available
     
     
     
220. TAS F, Erturk K
     Recurrence behavior in early-stage cutaneous melanoma: pattern, timing, survival, and influencing factors.
     Melanoma Res. 2017 Jan 17. doi: 10.1097/CMR.0000000000000332.
     PubMed     Text format     Abstract available
     
     
     
221. DE HAAN J, Lok CA, de Groot CJ, Crijns MB, et al
     Melanoma during pregnancy: a report of 60 pregnancies complicated by melanoma.
     Melanoma Res. 2017 Jan 17. doi: 10.1097/CMR.0000000000000327.
     PubMed     Text format     Abstract available
     
     
     
222. LV C, Dai H, Sun M, Zhao H, et al
     Mesenchymal stem cells induce epithelial mesenchymal transition in melanoma by paracrine secretion of transforming growth factor-beta.
     Melanoma Res. 2017 Jan 5. doi: 10.1097/CMR.0000000000000325.
     PubMed     Text format     Abstract available
     
     
     
223. BORRONI RG, Manganoni AM, Grassi S, Grasso M, et al
     Genetic counselling and high-penetrance susceptibility gene analysis reveal the novel CDKN2A p.D84V (c.251A>T) mutation in melanoma-prone families from Italy.
     Melanoma Res. 2017 Jan 4. doi: 10.1097/CMR.0000000000000324.
     PubMed     Text format     Abstract available
     
     
     December 2016
224. LINO-SILVA LS, Castillo-Medina AL, Salcedo-Hernandez RA, Garcia-Perez L, et al
     Exhaustive pathologic work-up in sentinel lymph node biopsy for melanoma: is it necessary?
     Melanoma Res. 2016 Dec 27. doi: 10.1097/CMR.0000000000000319.
     PubMed     Text format     Abstract available
     
     
     
225. MICEVIC G, Theodosakis N, Taube JM, Bosenberg MW, et al
     Attenuation of genome-wide 5-methylcytosine level is an epigenetic feature of cutaneous malignant melanomas.
     Melanoma Res. 2016 Dec 16. doi: 10.1097/CMR.0000000000000315.
     PubMed     Text format     Abstract available
     
     
     
226. BEHLING J, Kaes J, Munzel T, Grabbe S, et al
     New-onset third-degree atrioventricular block because of autoimmune-induced myositis under treatment with anti-programmed cell death-1 (nivolumab) for metastatic melanoma.
     Melanoma Res. 2016.
     PubMed     Text format     Abstract available
     
     
     
227. MININI R, Rohrmann S, Braun R, Korol D, et al
     Incidence trends and clinical-pathological characteristics of invasive cutaneous melanoma from 1980 to 2010 in the canton of Zurich, Switzerland.
     Melanoma Res. 2016.
     PubMed     Text format     Abstract available
     
     
     
228. PISCIOLI F, Pusiol T, Roncati L
     Thin melanoma subtyping fits well with the American Joint Committee on Cancer staging system.
     Melanoma Res. 2016;26:636.
     PubMed     Text format    
     
     
     
229. PISCIOLI F, Pusiol T, Roncati L
     Histopathological determination of thin melanomas at risk for metastasis.
     Melanoma Res. 2016;26:635.
     PubMed     Text format    
     
     
     November 2016
230. LEONTOVICH AA, Dronca RS, Nevala WK, Thompson MA, et al
     Effect of the lymphocyte-to-monocyte ratio on the clinical outcome of chemotherapy administration in advanced melanoma patients.
     Melanoma Res. 2016.
     PubMed     Text format     Abstract available
     
     
     October 2016
231. PAOLINO G, Panetta C, Cota C, Didona D, et al
     Vitamin D receptor immunohistochemistry variability in sun-exposed and non-sun-exposed melanomas.
     Melanoma Res. 2016.
     PubMed     Text format     Abstract available
     
     
     
232. SHOUSHTARI AN, Bluth MJ, Goldman DA, Bitas C, et al
     Clinical features and response to systemic therapy in a historical cohort of advanced or unresectable mucosal melanoma.
     Melanoma Res. 2016.
     PubMed     Text format     Abstract available
     
     
     
233. NGUYEN BH, Kuo J, Budiman A, Christie H, et al
     Two cases of clinical myasthenia gravis associated with pembrolizumab use in responding melanoma patients.
     Melanoma Res. 2016.
     PubMed     Text format     Abstract available
     
     
     
234. VARTANIAN A, Baryshnikova M, Burova O, Afanasyeva D, et al
     Inhibitor of vasculogenic mimicry restores sensitivity of resistant melanoma cells to DNA-damaging agents.
     Melanoma Res. 2016.
     PubMed     Text format     Abstract available
     
     
     
235. CHAKRAVARTI N, Ivan D, Trinh VA, Glitza IC, et al
     High cytotoxic T-lymphocyte-associated antigen 4 and phospho-Akt expression in tumor samples predicts poor clinical outcomes in ipilimumab-treated melanoma patients.
     Melanoma Res. 2016.
     PubMed     Text format     Abstract available
     
     
     
236. LIM MS, Wang JH, Power DG, Redmond HP, et al
     Inflammatory regulation of stem-like cells in melanoma.
     Melanoma Res. 2016.
     PubMed     Text format     Abstract available
     
     
     
237. ADAMS G, Foote M, Brown S, Burmeister B, et al
     Adjuvant external beam radiotherapy after therapeutic groin lymphadenectomy for patients with melanoma: a dosimetric comparison of three-dimensional conformal and intensity-modulated radiotherapy techniques.
     Melanoma Res. 2016.
     PubMed     Text format     Abstract available
     
     
     
238. BOTTLAENDER L, Perier-Muzet M, Lapras V, Thomas L, et al
     Tumor-free osteosclerotic lesions in patients treated for metastatic melanoma using BRAF inhibitors.
     Melanoma Res. 2016.
     PubMed     Text format     Abstract available
     
     
     
239. AMBER KT, Panganiban CM, Korta D, Feraudy S, et al
     A case report of bullous pemphigoid associated with a melanoma and review of the literature.
     Melanoma Res. 2016.
     PubMed     Text format     Abstract available
     
     
     
240. MATHESON JA, Te Marvelde L, Mailer S, Speakman D, et al
     Prospective evaluation of prognostic indicators for early recurrence of cutaneous melanoma.
     Melanoma Res. 2016.
     PubMed     Text format     Abstract available
     
     
     September 2016
241. KUBECEK O, Kopecky J
     Microsatellite instability in melanoma: a comprehensive review.
     Melanoma Res. 2016.
     PubMed     Text format     Abstract available
     
     
     
242. MIRJACIC MARTINOVIC KM, Babovic NL, Dzodic RR, Jurisic VB, et al
     Beneficial in-vitro effects of interleukin-2, interleukin-12, and their combination on functional and receptor characteristics of natural killer cells in metastatic melanoma patients with normal serum lactate dehydrogenase levels.
     Melanoma Res. 2016.
     PubMed     Text format     Abstract available
     
     
     April 2016
243. CHENG C, Yang HW, Shang JF, Li WW, et al
     Identification of a small molecule that downregulates MITF expression and mediates antimelanoma activity in vitro.
     Melanoma Res. 2016;26:117-24.
     PubMed     Text format     Abstract available
     
     
     
244. WANG LE, Li C, Xiong P, Gershenwald JE, et al
     4-nitroquinoline-1-oxide-induced mutagen sensitivity and risk of cutaneous melanoma: a case-control analysis.
     Melanoma Res. 2016;26:181-7.
     PubMed     Text format     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Malignant Melanoma is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: